In Clinical Trials or Post-Marketing
A validated approach to measuring the severity of psoriasis! Tracks PASI, yet easier to use and standardized. Takes less time than PASI and, unlike PASI, is consistent with FDA and EMA recommendations for psoriasis scoring.The system, called the Lattice System - Physician's Global Assessment (LS-PGA, U.S. pat.), is easy to use in clinical trials. Only four boxes are checked by the physician to derive the overall final score. For single target lesions, use the LS- Target PGA.
The score meets regulatory requirements, including a static score with intuitive results, eg, clear, severe. PASI is not approved by FDA for phase III trials.
LS-PGA has been validated and compared to PASI twice: Langley and Ellis, J Am Acad Dermatol, Oct 2004, http://www.eblue.org ; and Berth-Jones, Br J Dermatol.
The LS-PGA system may be accompanied by an optional booklet showing photo examples for rating psoriasis. A browser-based LS-PGA calculator is available.
An in-office LS-PGA is also available for post-marketing studies.
For more information, contact Charles N. Ellis, MD, Professor of Dermatology, University of Michigan Medical School.
info@datacquire.com
1-734-665-0493
